Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R31 | P59538 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 1/20 | 0.51 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | XDH | P47989 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4225984 | 1.00 | TAS2R31 (0.74) | TAS2R31NPC1RAB9ACYP1A1CYP1A2 | |
| SCHEMBL27775946 | 0.82 | IDO1 (0.49) | TAS2R31NPC1RAB9ACYP1A1CYP1A2 | |
| SCHEMBL382207 | 0.81 | TAS2R31 (0.79) | TAS2R31NPC1RAB9ACYP1A1CYP1A2 | |
| SCHEMBL12067074 | 0.81 | TAS2R31 (0.83) | TAS2R31NPC1RAB9ACYP1A1CYP1A2 | |
| SCHEMBL12067047 | 0.80 | TAS2R31 (0.81) | TAS2R31NPC1RAB9ACYP1A1CYP1A2 | |
| SCHEMBL20450286 | 0.78 | NPC1 (0.69) | TAS2R31NPC1RAB9ACYP1A1CYP1A2 | |
| SCHEMBL5551104 | 0.78 | NPC1 (0.69) | TAS2R31NPC1RAB9ACYP1A1CYP1A2 | |
| SCHEMBL12067049 | 0.78 | TAS2R31 (0.74) | TAS2R31NPC1RAB9ACYP1A1CYP1A2 | |
| SCHEMBL12067072 | 0.78 | TAS2R31 (0.74) | TAS2R31NPC1RAB9ACYP1A1CYP1A2 | |
| SCHEMBL27775449 | 0.77 | NPC1 (0.82) | TAS2R31NPC1RAB9ACYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016075543-A1 | TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND A PHOSPHODIESTERASE-4 (PDE4) INHIBITOR | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2016-05-19 | — | — | WO | claimed |
| US-20160045617-A1 | TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY | LEE JUSTIN C (US) | 2016-02-18 | — | — | US | claimed |
| WO-2014169087-A2 | TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-10-16 | — | — | WO | claimed |
| US-20140127328-A1 | METHODS AND COMPOSITIONS FOR TREATING ANXIETY DISORDERS OR SYMPTOMS THEREOF | PONDERA BIOTECHNOLOGIES INC. (US) | 2014-05-08 | — | — | US | claimed |
| US-20130156874-A1 | METHODS AND COMPOSITIONS FOR TREATING DISTRESS DYSFUNCTION AND ENHANCING SAFETY AND EFFICACY OF SPECIFIC MEDICATIONS | Pondera Biotechnologies, LLC (US) | 2013-06-20 | — | — | US | claimed |
| US-20120237570-A1 | METHODS AND COMPOSITIONS FOR TREATING DISTRESS DYSFUNCTION AND ENHANCING SAFETY AND EFFICACY OF SPECIFIC MEDICATIONS | Pondera Biotechnologies, LLC | 2012-09-20 | — | — | US | claimed |
| WO-2011087755-A2 | METHODS AND COMPOSITIONS FOR TREATING DISTRESS DYSFUNCTION AND ENHANCING SAFETY AND EFFICACY OF SPECIFIC MEDICATIONS | Pondera Biotechnologies, LLC (US) | 2011-07-21 | — | — | WO | claimed |
| US-20110159048-A1 | METHODS AND COMPOSITIONS FOR TREATING DISTRESS DYSFUNCTION AND ENHANCING SAFETY AND EFFICACY OF SPECIFIC MEDICATIONS | Pondera Biotechnologies, LLC | 2011-06-30 | — | — | US | claimed |
| US-20090270495-A1 | Inhibitors of Phosphodiesterase Types 1 To 5 Based on Dioclein, Floranol, and Analogs Thereof | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2009-10-29 | — | — | US | claimed |
| EP-1877049-A2 | INCLUSION COMPOUNDS OF DIOCLEIN, FLORANOL OR ANALOGS WITH CYCLODEXTRIN AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES | Universidade Federal de Minas Gerais (BR) | 2008-01-16 | — | — | EP | claimed |
| WO-2006102728-A2 | INCLUSION COMPOUNDS OF DIOCLEIN, FLORANOL OR ANALOGS WITH CYCLODEXTRIN AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2006-10-05 | — | — | WO | claimed |
| US-12350283-B2 | Methods and compositions for treating motor neuron diseases | UNIVERSITAT DE VALENCIA-ESTUDI GENERAL (ES) | 2025-07-08 | — | — | US | disclosed |
| CN-113473993-B | Methods and compositions for treating motor neuron diseases | 巴伦西亚大学 | 2024-06-04 | — | — | CN | disclosed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | disclosed |
| WO-2006102728-A2 | INCLUSION COMPOUNDS OF DIOCLEIN, FLORANOL OR ANALOGS WITH CYCLODEXTRIN AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006102728-A2 | INCLUSION COMPOUNDS OF DIOCLEIN, FLORANOL OR ANALOGS WITH CYCLODEXTRIN AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2006-10-05 | — | — | WO | disclosed |
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| CN-1780823-A | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC (JP) | 2006-05-31 | — | — | CN | disclosed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | PTPN11, PTPN1, PTPN3 | TAS2R31 2455/4885NPC1 955/4885RAB9A 1393/4885 |
| US-20090270495-A1 | Inhibitors of Phosphodiesterase Types 1 To 5 Based on Dioclein, Floranol, and Analogs Thereof | PDE5A, PDE12, PDE2A | TAS2R31 3553/4885NPC1 3873/4885RAB9A 2521/4885 |
| US-20160045617-A1 | TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY | CELF2, SMN1; SMN2, GRM8 | TAS2R31 1760/4885NPC1 4464/4885RAB9A 1309/4885 |
| US-12350283-B2 | Methods and compositions for treating motor neuron diseases | SMN1; SMN2, NNMT, PDE4A | TAS2R31 3401/4885NPC1 3534/4885RAB9A 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.